VCEL News and Press, Vericel Corporation From 01/01/23

Summary Various ongoing fundamental improvements signal significant upsides. The recent NexoBrid approval foretells leaping sales growth in the coming quarters. The lead franchise (Maci) is enjoying aggressive revenue growth that is far exceeding my expectations. ...

The shares of Vericel Corporation ( NASDAQ: VCEL ) and MediWound Ltd. ( NASDAQ: MDWD ) rose on Thursday on the FDA approval of NexoBrid, a botanical drug product the companies collaborated to develop as a treatment for thermal burns. Specifically, the FDA has greenlighted Nexo...

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Triggers $7.5 million milestone payment from Vericel Corporation; NexoBrid is anticipated to be commercially available in the U.S. in the second quarter of...

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Label supported by robust clinical data demonstrating significantly higher incidence of complete eschar removal in patients treated with NexoBrid compared ...

Palm Beach, FL – November 15, 2022 – FinancialNewsMedia.com News Commentary – Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one factor driving expansion in the COPD drug ...

Summary In today's issue of the 1-Minute Market Report, I examine the market bounce since the October low, and highlight the areas of the market that are leading the way higher. On Thursday, for every stock that was down, there were 26 that were up. For the first time since August...

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digita...

Truist analysts led by Samuel Brodovsky slashed their rating on Vericel Corporation ( NASDAQ: VCEL ) on Wednesday to Hold from Buy after the commercial-stage biotech disappointed Wall Street with its Q3 2022 results. Citing a balanced risk/reward and valuation that imp...

Vericel Corporation (VCEL) Q3 2022 Earnings Conference Call November 09, 2022, 08:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investor Relations Nick Colangelo - President & Chief Executive Officer Joe Mara - Chief...

Vericel press release ( NASDAQ: VCEL ): Q3 GAAP EPS of -$0.14 misses by $0.04 . Revenue of $38.6M (+11.9% Y/Y) misses by $1.3M . MACI ® net revenue of $31.0 million, Epicel ® net revenue of $7.3 million, and NexoBrid ® revenue of $0.2...